ReviewFrontiers in endocrinology2023
Can type 1 diabetes be an unexpected complication of obesity?
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.International journal of molecular sciences · 2026Pooled it
- Islet Autoantibodies in Adult With Pituitary and Ovarian Autoimmunity: Implications for Type 1 Diabetes Screening.Diabetes, obesity & metabolism · 2026Article
- The Bidirectional Relationship Between Type 1 Diabetes Mellitus and Obesity in Pediatric Patients: A Systematic Review.Children (Basel, Switzerland) · 2026Review
- The progress and challenges of mesenchymal stromal cell-based therapy for diabetes and its complications.Biological research · 2026Review
- Functional Foods as Modulators of Epigenetic Mechanisms Affecting Metabolic Health in Adolescence.International journal of molecular sciences · 2026Review
- A commentary on "High prevalence of metabolic comorbidities in Asian children with type 1 diabetes and obesity".Annals of pediatric endocrinology & metabolism · 2026Article
- Nutritional myths in adolescents and young adults with type 1 diabetes: a pilot study.BMC nutrition · 2025Article
- Scaffold-free endocrine tissue engineering: role of islet organization and implications in type 1 diabetes.BMC endocrine disorders · 2025Review
- Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.Journal of clinical medicine · 2025Review
- Macrophages: friend or foe in diabetes pathogenesis and therapy.Frontiers in immunology · 2025Review
- Drawing lines in the sand: The growing threat of obesity in type 1 diabetes.World journal of diabetes · 2024Article
- Investigating the Incidence of Dyslipidemia among Brazilian Children and Adolescents Diagnosed with Type 1 Diabetes Mellitus: A Cross-Sectional Study.Diseases (Basel, Switzerland) · 2024Article
- Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?Frontiers in endocrinology · 2024Review
- The Anti-Diabetic Potential of Baicalin: Evidence from Rodent Studies.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) is one of the most common chronic autoimmune diseases, characterized by absolute insulin deficiency caused
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.